Key Highlights
● Lycia closed at $30.92 on Tuesday, 17 November.
● Guggenheim started at Buy with a $75 target.
● Jefferies set $50, LifeSci Capital $48 and Evercore ISI $43.
● All targets sat above the closing price.
Lycia Therapeutics (NASDAQ:LYCA) rose on Tuesday, 17 November 2026, closing at $30.92 after a cluster of Investment banks launched coverage of the recently public drug developer, all with positive ratings.
Guggenheim started the stock at Buy with a $75 price target. Jefferies (NYSE:JEF) initiated at Buy with a $50 target, LifeSci Capital began at Outperform with a $48 target, and Evercore (NYSE:EVR) ISI opened at Outperform with a $43 target. TD Cowen also initiated coverage with a Buy rating.
Why the timing matters
When a company goes public, the banks that helped underwrite the offering are generally barred from publishing research on it for a set period afterward, often called the quiet period. Once that window ends, those firms frequently publish initial reports on the same day, creating a burst of coverage.
The simultaneous initiations on Lycia fit that pattern, which likely marks the end of its post-IPO quiet period. Available information did not say which of these firms, if any, worked on the company's initial public offering. Either way, the reports reflect each firm's own analysis and assumptions, and price targets are estimates, not guarantees.
Every target issued Tuesday sat above Lycia's closing price, ranging from $43 at Evercore ISI to $75 at Guggenheim. The wide spread between the lowest and highest targets shows how much analysts' views on the company's prospects can differ.
About Lycia
Lycia Therapeutics is a biotechnology company that recently completed its initial public offering and has not yet been added to major indexes. Early-stage biotech companies typically have no product Revenue and rely on investor funding to advance their drug programs through clinical trials. Their valuations depend heavily on expectations for future trial results and eventual approvals.
For a newly listed company, analyst coverage can also broaden the investor base. Research reports help institutional investors understand a company's science, competitive landscape and potential market, which can increase trading interest and Liquidity in shares that have only a short public history.
Gains against a falling market
Lycia's advance came as the broader market slid. The Nasdaq Composite lost 181.37 points to 24,328.38, after being down far more earlier in the day. The Russell 2000 index of small companies fell 41.07 points to 2,701.87, its lowest close since April 13. In the S&P 500, health care was among the weakest sectors, hurt by a drop in managed-care stocks.
Biotech produced some of the session's most dramatic moves. SELLAS Life Sciences (NASDAQ:SLS) more than doubled after a late-stage leukemia trial met its main goal, Greenwich LifeSciences (NASDAQ:GLSI) surged after announcing acceptance of abstracts for a breast cancer conference, and Iambic Therapeutics, another recent IPO, also jumped. On the downside, Kyntra Bio (NASDAQ:KYNB) plunged after ending a Phase 2 trial, and Cue Biopharma (NASDAQ:CUE) collapsed without an identified catalyst.
The CBOE Volatility Index rose to 25.45, reflecting heightened nerves across Wall Street, and Nasdaq new lows far outnumbered new highs.
What to watch
Investors will look for any further coverage initiations, along with company updates on clinical programs and timelines for upcoming data. For a recently public biotech, the first Earnings report and any presentations at medical or investor conferences can be important moments. Broader appetite for risk, shaped by Federal Reserve minutes due Wednesday and the Anthropic IPO on Thursday, may also influence trading in small, speculative stocks like Lycia.
Coverage Broadens the Investor Base
Analyst coverage can broaden a newly listed company's investor base and trading liquidity. Price targets are estimates, not guarantees, and the wide spread shows how much views on the company differ.






Please wait processing your request...